'Cox model' diaporamas de présentation

Survival Analysis II

Survival Analysis II. Reading VGSM 6.2.5 - 6.2.13. John Kornak April 9, 2013 John.kornak@ucsf.edu. Project description due today Hwk #1 due next Tuesday, 4/16 to Olivia De Leon Reading for next lecture VGSM 6.3 - 6.5 Lab. 2 on web site - for this Thursday Rm 6702/6704

807 views • 65 slides

Survival Analysis III

Survival Analysis III. John Kornak April 10, 2012 john.kornak@ucsf.edu. Reading VGSM 7.3 - 7.5. Homework # 1 due Today in class Homework Q/A after class today 12-1 Lab 3 on Thursday 10.30 - 6702 & 6704 Homework #2 due next Tuesday (4/19) in class VGSM 2012 is now available.

920 views • 63 slides

Subgroup Analysis

1.3k views • 46 slides

Survival comorbidity Mrs Retha Steenkamp Senior Statistician UK Renal Registry

Survival comorbidity Mrs Retha Steenkamp Senior Statistician UK Renal Registry. UK Renal Registry 2011 Annual Audit Meeting. Importance of co-morbidities in survival. Co-morbidities collected by the Renal Registry Missing co-morbidities Accuracy of co-morbidities Importance of co-morbidities.

594 views • 42 slides

Anemia

Anemia. CBC, retic count. Retics normal or increased. Hypoproliferative. Hypoproliferative. Marrow damage > Infiltration; fibrosis > Aplasia > Myelodysplasia > Drug or radiation injury Iron deficiency B12 deficiency Folate deficiency Stimulus > Inflammation

808 views • 41 slides

Multiple Regression

Multiple Regression. Multiple Regression - Overview . Multiple Regression in statistics is the science and art of creating an equation that relates an outcome Y, to one or more predictors, X 1 , X 2 , X 3 , .. X k . Linear Regression

783 views • 40 slides

HSRP 734: Advanced Statistical Methods July 24, 2008

HSRP 734: Advanced Statistical Methods July 24, 2008. Objectives. Describe methods to evaluate the proportional hazard assumption Describe other model diagnostics Describe a stratified analysis Use SAS to implement. Background.

472 views • 36 slides

565 views • 35 slides

EPI 5344: Survival Analysis in Epidemiology Confounding and Effect Modification March 25, 2014

EPI 5344: Survival Analysis in Epidemiology Confounding and Effect Modification March 25, 2014. Dr. N. Birkett, Department of Epidemiology & Community Medicine, University of Ottawa. Objectives. Review confounding and effect modification (EM) Graphical view of confounding and EM

576 views • 35 slides

Survival Analysis

Survival Analysis. Key variable = time until some event. time from treatment to death time for a fracture to heal time from surgery to relapse. Censored observations. subjects removed from data set at some stage without suffering an event

1.35k views • 32 slides

11 th Annual Symposium on Prostate Cancer

483 views • 29 slides

Retroperitoneal Sarcomas (RPS)

Patterns of Care and Prognosis of Retroperitoneal Sarcomas in the Primary and Advanced Settings A Large Multicentric Retrospective Analysis from the French Sarcoma Group .

548 views • 28 slides

HSRP 734: Advanced Statistical Methods July 31, 2008

HSRP 734: Advanced Statistical Methods July 31, 2008. Objectives. Describe the general form of the Cox proportional hazards model extended for time-dependent variables Describe the analysis for staggered entry Review for Final exam. Time-Dependent Variables.

412 views • 28 slides

A Novel Approach To Search For Dominant Risk Factors

A Novel Approach To Search For Dominant Risk Factors. Presented by Dr. Ke-Shiuan Lynn Sep. 17 2004. A Conventional Approach. Cox Proportional Hazard Model Let there be n covariates. The Cox model assumes that the hazard function ?(t) can be approximated by

346 views • 25 slides

Cox Model With Intermitten and Error-Prone Covariate Observation

Cox Model With Intermitten and Error-Prone Covariate Observation. Yury Gubman PhD thesis in Statistics Supervisors: Prof. David Zucker, Prof. Orly Manor. Introduction. Regression analysis of right-censored survival data commonly arises in many fields, especially in medical science.

338 views • 20 slides

280 views • 19 slides

Empirical Likelihood

172 views • 17 slides

Use of Rosiglitazone in the BARI 2D Trial

Use of Rosiglitazone in the BARI 2D Trial. David Gordon, M.D., Ph.D. Division of Cardiovascular Diseases National Heart, Lung, and Blood Institute Executive Secretary and ex-Project Officer, BARI 2D DSMB. PI: Sheryl Kelsey, University of Pittsburgh Study Chair: Robert Frye, Mayo Clinic

289 views • 15 slides

I nternational E pidemiologic D atabases to E valuate AIDS

18-month mortality and loss to follow-up in ART-treated children in Asia and Africa The pediatric IeDEA multiregional collaboration Leroy, V.1, Malateste K. 1, Rabie H. 2, Pagakrong L.3, Ayaya S. 4, Dicko, F. 5,

386 views • 15 slides

Fig. 1: Relapse-free survival in the TIL + IL-2 group: this difference was not significant (p=0.45; log-rank test); 16.7 years median follow-up. Fig. 2. : Cox model curves for the conditions Breslow >1.5, capsular breaking and only one invaded lymph node.

147 views • 4 slides